Newer medications that got the green light from the US Food and Drug Administration had more than a one in four likelihood of receiving a black box warning or being withdrawn from the market within 25 years of their approval, according to new research. Cassie Frank, instructor in medicine at Cambridge Health Alliance, was the lead author of the study.
News & Research
